Abstract
Introduction Cost and drug toxicity often deter prolonged therapeutic use of anti-TNF agents in ankylosing spondylitis (AS). A planned study was completed to endorse our clinic-based observation of long-term relief following short-term administration of an anti-TNF agent.
Methods 50 consenting patients with symptomatic active chronic AS under rheumatology care in a community clinic were enrolled; naïve for anti-TNF. 40 mg standard biosimilar Adalimumab (Bs-ADA, Exemptia™) was injected subcutaneously every fortnight for six injections (10 weeks). Patients were monitored at several predetermined time points. Improvement was assessed with standard indices (Assessment Spondyloarthritis International Society/ASAS and Bath). An intention to treat analysis was performed: significant p <0·05
Results Patients showed early and substantial significant improvement in pain, NSAID requirement, function, and in several indices (ASAS 20 & 40, ASAS partial remission, BASDAI, BASFI, ASDAS) which persisted after stopping injections. 84% and 52 % of patients respectively showed ASAS 20 improvement at weeks 12 and 48: corresponding to ASAS partial remission at 34% and 24%. Over 50% of patients maintained prolonged improvement and provided proof of concept (defined apriori). Serum Interleukin-6 assay showed a sharp reduction at 24 weeks. None developed TB or serious drug toxicity. 11 patients withdrew (mostly inadequate response). The absence of control was a limitation.
Conclusion A ten-week administration of biosimilar adalimumab in difficult-to-treat AS showed early substantial improvement which often persisted for 24 weeks. This unconventional strategy was socioeconomically appealing. It merits further validation and acceptance, especially in resource strained settings.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
India: CTRI/2018/02/012018 dated 20 Feb 2018 (retrospectively registered)
Funding Statement
Zydus Cadila India donated a substantial quantity of biosimilar Adalimumab (Exemptia trade name) injections for free use by the deserving and needy patient participants in the study and further provided an unrestricted educational and research grant to Arthritis Research Care Foundation-Centre for Rheumatic Diseases CRD), Pune, India.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of Centre for Rheumatic Diseases, Pune, India gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵** Mihir
Address for Communication: Dr Arvind Chopra, Centre for Rheumatic Diseases., Hermes Elegance, 1988 Convent St., Camp, Pune, 411001 India
Drug Trial Registration: Clinical Trial Registry of India vide reference CTRI/2018/02/012018 and available at http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=19498&EncHid=&userName=adalimumab.
Disclosures: All the authors of the current study are full time employees of CRD Pune and did not receive any personal payment or compensation from any source towards the current study or current publication.
Conflicts of interest/Competing Interest: It is confirmed by Arvind Chopra (first author) that neither he nor any of the current authors has any conflict of interest.
Funding: Zydus Cadila India donated a substantial quantity of biosimilar Adalimumab (Exemptia™) injections for free use by the deserving and needy patient participants in the study and further provided an unrestricted educational and research grant to Arthritis Research Care Foundation-Centre for Rheumatic Diseases CRD), Pune, India.
Availability of data and material: All study related medical and other records are archived in Centre for Rheumatic Diseases (CRD), Pune, India. An e-database was created to capture the data required for study analysis and access will be provided one year after publication after a formal request inclusive of purpose of data access to the first author (Dr Arvind Chopra) of the current study.
Ethics approval: Approval was obtained from the ethics committee of the Centre for Rheumatic Diseases, Pune, India, and the procedures used in this study adhere to the tenets of the Declaration of Helsinki. Arvind Chopra, Manjit Saluja
Consent to participate: Informed consent was obtained from all individual participants included in the study.
Consent for publication: No specific data or photograph of any kind of a study participant is used in this study.
Data Transparency: All data and materials as well as software application or custom code used in the current study support the data presented and claims made in the current study and comply with the field standards of scientific writing, credibility, authenticity and personal honesty.
An additional author has been added and the author affiliation revised. Survival analysis results using indices of AS activity are added. Several grammatical errors were corrected.
Data Availability
All data produced in the present work are contained in the manuscript and any further data required will be made available upon reasonable request to the authors 6 months after publication
